GHRP-2 vs IGF-1 DES
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHRP-2
GHRP-2 is a synthetic hexapeptide that acts as a ghrelin mimetic, stimulating the pituitary gland to secrete growth hormone (GH). It is one of the most potent GH secretagogues studied, producing stronger GH pulses than GHRP-6 with comparatively less appetite stimulation.
Full profileIGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profile| GHRP-2 | IGF-1 DES | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Growth Hormone Releasing Peptide-2, Pralmorelin, KP 102 | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) |
| Key side effects | Increased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritation | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: GHRP-2 is preclinical only, while IGF-1 DES is research-stage.
- Administration: GHRP-2 — Subcutaneous injection, Intramuscular injection; IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect).
- Frequency: GHRP-2 is typically 1–3 times daily, on an empty stomach; IGF-1 DES is 1–2x daily, preferably post-workout.
- Research depth: this profile cites 3 sources for GHRP-2 vs 2 for IGF-1 DES.
How each works
GHRP-2
GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.